History of Dexamethasone in Timeline

Dexamethasone, a glucocorticoid medication, effectively treats various health conditions such as rheumatic problems, skin diseases, allergies, respiratory issues, brain swelling, and eye pain. It is also used in treating adrenocortical insufficiency, preterm labor complications, and tuberculosis. Administration routes include oral, injection, topical cream, and eye drops. Its effects typically manifest within a day and persist for approximately three days.

1957: Dexamethasone First Synthesized

Philip Showalter Hench first synthesized Dexamethasone in 1957.

1958: Dexamethasone Approved for Medical Use

Dexamethasone was approved for medical use in 1958.

June 2020: RECOVERY Trial Announces Preliminary Results on Dexamethasone for COVID-19

On June 16, 2020, the RECOVERY Trial announced preliminary results showing dexamethasone improved survival rates in hospitalized COVID-19 patients receiving oxygen or on a ventilator.

July 2020: WHO Cautions on Dexamethasone Use, Announces Guideline Update

In July 2020, the World Health Organization (WHO) stated dexamethasone should be reserved for seriously ill or critical hospitalized COVID-19 patients, emphasizing potential harm for milder cases. They announced an update to treatment guidelines to include dexamethasone or other steroids.

July 2020: Preliminary Report on Dexamethasone in COVID-19 Published

The preliminary report on the RECOVERY trial for Dexamethasone was published in The New England Journal of Medicine in July 2020.

September 2020: EMA Endorses Dexamethasone for COVID-19

In September 2020, the European Medicines Agency (EMA) endorsed the use of dexamethasone in adults and adolescents (12 years and older, weighing at least 40 kg) who require supplemental oxygen therapy for COVID-19.

September 2020: WHO Updates Guidance on Corticosteroids for COVID-19

In September 2020, the WHO released updated guidance on using corticosteroids, including dexamethasone, for COVID-19.

November 2020: Canadian Agency Recommends Dexamethasone, Notes Risks

In November 2020, the Public Health Agency of Canada's Clinical Pharmacology Task Group recommended dexamethasone for hospitalized patients requiring mechanical ventilation, but acknowledged an increased risk of secondary infections.